Patent · US Active

Immunoglobulin single variable domain antibody against RSV prefusion F protein

US10501528B2 · kind B2 · utility

1Cited by

0References

12Claims

0Family size

Assignees

V18 VZW · BE
UNIVERSITEIT GENT · BE
The United States of America, as represented by the Secretary, Health and Human Services · US
TRUSTEES OF DARTMOUTH COLLEGE · US

Inventors

Xavier Saelens · Ieper, BE
Bert Schepens · Evergem, BE
Iebe Rossey · Gentbrugge, BE
Barney Graham · Rockville, US
Jason McLellan · Austin, US
Morgan Gilman · White River Junction, US

Key dates

Filing date	Jun 20, 2016
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Jun 20, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.